These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8584586)

  • 1. Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.
    Schooler NR; Keith SJ; Severe JB; Matthews SM
    Psychiatr Q; 1995; 66(4):279-92. PubMed ID: 8584586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
    Schooler NR; Keith SJ; Severe JB; Matthews SM; Bellack AS; Glick ID; Hargreaves WA; Kane JM; Ninan PT; Frances A; Jacobs M; Lieberman JA; Mance R; Simpson GM; Woerner MG
    Arch Gen Psychiatry; 1997 May; 54(5):453-63. PubMed ID: 9152099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for enhancing drug therapy of schizophrenia.
    Schooler NR; Levine J
    Am J Psychother; 1983 Oct; 37(4):521-32. PubMed ID: 6140869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
    Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
    Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.
    Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
    Schizophr Res; 2002 Jan; 53(1-2):145-59. PubMed ID: 11728846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy of persons with schizophrenia.
    Carpenter WT
    J Clin Psychiatry; 1996; 57 Suppl 9():10-8. PubMed ID: 8823345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention.
    Francey SM; Nelson B; Thompson A; Parker AG; Kerr M; Macneil C; Fraser R; Hughes F; Crisp K; Harrigan S; Wood SJ; Berk M; McGorry PD
    Schizophr Res; 2010 Jun; 119(1-3):1-10. PubMed ID: 20347270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of relapse in schizophrenia.
    Weiden PJ; Olfson M
    Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early, targeted pharmacotherapeutic intervention in schizophrenia.
    Carpenter W
    J Clin Psychiatry; 1986 May; 47 Suppl():23-9. PubMed ID: 2871012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose antipsychotic medication.
    Will D; Wrate RM; Bhate S; Taylor P; James T; Rothery D; Clark A
    Br J Psychiatry; 1994 Aug; 165(2):269-70. PubMed ID: 7953047
    [No Abstract]   [Full Text] [Related]  

  • 16. Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification.
    Müller P; Bandelow B; Gaebel W; Köpcke W; Linden M; Müller-Spahn F; Pietzcker A; Schaefer E; Tegeler J
    Br J Psychiatry Suppl; 1992 Oct; (18):140-4. PubMed ID: 1356364
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
    Leucht S; Heres S
    J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rehabilitation in schizophrenia--guidelines for including psychosocial measures].
    Katschnig H
    Wien Med Wochenschr; 1998; 148(11-12):273-80. PubMed ID: 9746970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive psychosocial therapies for the treatment of schizophrenia.
    Patterson TL; Leeuwenkamp OR
    Schizophr Res; 2008 Mar; 100(1-3):108-19. PubMed ID: 18226500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review.
    Schooler NR
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():73-80. PubMed ID: 8866768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.